Precision Medicine Market to Reach $179.4 Billion by 2034

The global precision medicine market reached USD 82.1 billion in 2025 and is expected to grow to USD 179.4 billion by 2034, representing a CAGR of 8.63% during the forecast period 2026-2034. This growth is driven by major advancements in genomics, personalized healthcare, and technological innovations including AI and big data analytics.

As the market expands, researchers emphasize that precision nutrition interventions must consider cost-effectiveness to deliver benefits to patients. Precision nutrition interventions for type 2 diabetes that reduce medication use or healthcare visits even in the short-term are likely cost-effective.

The concept of precision nutrition — tailoring diets to individuals — attempts to optimize treatments in a similar way that precision medicine attempts to optimize treatments for individual patients. As gut bacteria contribute to variations in our responses to food, researchers have been investigating whether knowledge of individual microbiomes might help guide personalized nutrition approaches.

When we consume food, we are not just nourishing ourselves, we are also feeding the tens of trillions of microbes that live in our guts. That is one potential reason why people might respond differently to the same diet — they have a different mix of bacteria making up their microbiomes.

Researchers at Japanese snack and cereal manufacturer Calbee have been exploring whether prebiotics — such as some kinds of dietary fibre — might play a role in building and sustaining healthy gut flora. Prebiotics provide the food that some useful gut bacteria need to thrive, whereas probiotics add good bacteria to the gut.

In experiments in the lab, they used a special bioreactor system which mimics conditions in the human gut to find out how different bacterial species respond to different prebiotics which could be added to granola. The researchers observed an increase in the total populations of gut bacteria when the bioreactor system was supplied with granola supplemented with prebiotics than when it was fed with granola that was not supplemented with prebiotics.

The researchers monitored levels of short-chain fatty acids, which are metabolites produced by gut bacteria that studies have indicated may be beneficial to health. They found that when the bioreactors were fed with prebiotic-containing granola, the production of short-chain fatty acids was higher than in bioreactors fed with granola that did not contain prebiotics. These have been studied by scientists globally to explore potential effects on bowel movement, gut barrier strength, obesity, blood sugar regulation, inflammation and immunity.

Based on the research conducted, the company has developed a personalized nutrition subscription service that offers six different prebiotics for granola, which they argue could better suit different mixtures of gut bacteria. More than 40,000 people have had their gut flora analysed since the programme launched in Japan in 2023.

Growing demand for personalized treatments and advancements in genomic technologies significantly drive the precision medicine market. Innovations like high-throughput sequencing and bioinformatics enable faster, cost-effective genome sequencing, facilitating targeted therapies based on individual genetics. These advances support therapies that improve outcomes while minimizing adverse effects.

The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases further boosts demand. Precision medicine offers personalized treatments tailored to genetic profiles, enhancing treatment efficacy and reducing healthcare costs by minimizing trial and error.

Substantial investments in research and development from government bodies, private firms, and philanthropic organizations accelerate the discovery of novel biomarkers and companion diagnostics. This financial backing fosters innovation, pipeline development, and the translation of scientific breakthroughs into clinical applications.

Oncology holds the largest share among applications due to targeted cancer therapies. North America leads with the largest market share driven by robust healthcare infrastructure and R&D investments. Key challenges include high costs and complex regulatory environments, presenting opportunities for cost reduction and regulatory strategy innovation.